Key result
Trans-pulmonary sampling detects ~10% higher CYFRA and HE4 levels versus peripheral veins in lung cancer.
Why the study?
Measurement of tumor markers from peripheral venous blood is an emerging tool for early lung cancer diagnosis, but trans-pulmonary samples may increase diagnostic yield due to proximity to lung tumors.
Does trans-pulmonary sampling increase the diagnostic yield of tumor markers for lung cancer compared to peripheral venous sampling?
Case Report (n=1)
No
Does trans-pulmonary sampling increase the diagnostic yield of tumor markers for lung cancer compared to peripheral venous sampling?
Trans-pulmonary sampling via right-heart catheterization may yield higher concentrations of lung cancer tumor markers compared to peripheral venous sampling, suggesting a potential role in early diagnosis.
Answers are grounded in this paper and cite their sources.
Trans-pulmonary marker elevation seen in one recurrent SCLC case; leaves open whether sampling improves diagnostic yield over peripheral venous blood.
BACKGROUND: Measurement of tumor markers from peripheral venous blood is an emerging tool to assist in the early diagnosis of lung cancer. Samples from the pulmonary artery and pulmonary artery wedge position (trans-pulmonary samples) are accessible via right-heart catheterization and, by virtue of their proximity to lung tumors, may increase diagnostic yield. CASE PRESENTATION: We report a case of a 64 year-old woman from whom trans-pulmonary samples were obtained and who was diagnosed 16 months later with recurrent metastatic small cell lung cancer. Carcinoembryonic antigen, cytokeratin fragment 21 - 1 (CYFRA), and human epididymis protein 4 (HE4) levels demonstrated increasing concentrations across the pulmonary circulation. These gradients exceeded the assays' coefficient of variation by several-fold. For CYFRA and HE4, pulmonary artery wedge concentrations exceeded peripheral venous levels by more than 10% and peripheral arterial levels were up to 8% higher than peripheral venous levels. CONCLUSIONS: Evaluating the feasibility and utility of trans-pulmonary tumor markers for lung cancer diagnosis in a larger cohort should be considered. The addition of a peripheral arterial sample to standard peripheral venous samples may be a more practical alternative.
No takes yet. Share an insight, caveat, or question.
Monahan et al. (2024) conducted a case report in Small cell lung cancer (n=1). Trans-pulmonary sampling of tumor markers vs. Peripheral venous sampling was evaluated on Trans-pulmonary gradient of tumor markers (CEA, CA-125, CYFRA, HE4). In a patient later diagnosed with recurrent small cell lung cancer, trans-pulmonary concentrations of tumor markers CYFRA and HE4 exceeded peripheral venous levels by more than 10%.
Synapse has enriched 10 related papers. Consider them for comparative context: